Bone News and Research

RSS

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) have been awarded a grant of almost $1.5 million by the National Institutes of Health for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments.

6 May 2010

Proper nutrition during multi-day stage races may prevent harmful changes in bone turnover: Study

The recent start of the North American cycling season marks the beginning of a physically demanding time for elite and professional bicycle racers who participate in multi-day stage races. Previous research has found that competitive cyclists have significantly lower bone mineral density than other endurance athletes, making them more susceptible to fractures.

6 May 2010

New York federal court jury favors Merck in Maley FOSAMAX case

Merck today said a unanimous federal court jury in New York found in its favor in the Maley v. Merck case, rejecting the claims of a plaintiff who blamed her dental and jaw-related problems on her FOSAMAX use.

6 May 2010

Whole body MRI helps physicians diagnose and treat breast cancer: Study

Whole body magnetic resonance imaging should be the imaging modality of choice for the detection of breast cancer metastases (when the cancer has spread beyond the breast) as it is highly accurate and can detect bone metastases while a patient is still asymptomatic (shows no symptoms), according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

6 May 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

New test indicates bone marrow cell therapy may benefit MS patients

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

DGIMED ORTHO receives 510(k) clearance for DISTALOCK Titanium Femoral Intramedullary Nail system

DGIMED ORTHO, Inc. announced today that the company has received notification of clearance of its 510(k) submission for the DISTALOCKTM Titanium Femoral Intramedullary Nail system. In November 2009, the Company also received its initial clearance on the DISTALOCKTM Drill system with a stainless steel femoral IM nail.

6 May 2010

Making stem cells in the lab: a training program and a study

Young researchers will now be trained for the first time by the Australian Stem Cell Centre (ASCC) in scientific techniques of using and growing human induced pluripotent stem (iPS) cells in research. This training will be through StemCore iPS Cell Workshop, the ASCC's national facility for the provision of stem cells and advice.

5 May 2010

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).

5 May 2010

Study shows training in rhythmic gymnastics improves bone health in adolescent girls

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism, long-term elite rhythmic gymnastics exerts positive effects on volumetric bone density and bone geometry in adolescent girls.

5 May 2010

Investment report on Misonix from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Misonix Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

5 May 2010

ARIAD restructures collaboration with Merck for ridaforolimus mTOR inhibitor

ARIAD Pharmaceuticals, Inc. today announced that it has restructured its July 2007 collaboration with Merck, Sharpe & Dohme Corp. for the development, manufacture, and commercialization of ridaforolimus - ARIAD's investigational mTOR inhibitor.

5 May 2010

$Seniors who consume high dietary protein are less likely to suffer hip fractures$

Seniors who consume high dietary protein are less likely to suffer hip fractures

Seniors who consume a higher level of dietary protein are less likely to suffer hip fractures than seniors whose daily dietary protein intake is less, according to a new study by the Institute for Aging Research of Hebrew SeniorLife in Boston, an affiliate of Harvard Medical School.

5 May 2010

States rely on federal funds to buttress Medicaid programs; Worry about the future

Late last year, when Congress' willingness to pass an enormous health care bill still was very much in doubt, states had a more modest goal that should have been easier to achieve. They wanted Congress to pass a 6-month extension of the part of the economic stimulus program that is helping to pay for their Medicaid programs.

5 May 2010

AdvaCAL named official partner of National Osteoporosis Foundation

AdvaCAL® calcium supplements is proud to announce that it has been named as an official partner of the National Osteoporosis Foundation (NOF), the nations' leading voluntary health organization dedicated to osteoporosis and bone health. This designation is reserved for companies that provide financial support to NOF, with products judged to be consistent with the NOF mission.

5 May 2010

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.

5 May 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.

4 May 2010

Clinical development of RG7128 is on track: Pharmasset

Pharmasset, Inc., in response to certain inaccuracies in an article published by PharmaWire on May 3, 2010 about its development program for treatment of hepatitis C virus in collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, stated today that the development of RG7128 is on track, and that no safety or other concerns have delayed the program.

4 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

Surgeons can now customize artificial knee implants, prevent future revision surgeries

Throughout the years orthopedic surgeons have learned that one size does not fit all when it comes to joint replacements. Because of advancements in technology, surgeons can now customize artificial knee implants and prevent future revision surgeries.

4 May 2010

Bone News and Research

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Proper nutrition during multi-day stage races may prevent harmful changes in bone turnover: Study

New York federal court jury favors Merck in Maley FOSAMAX case

Whole body MRI helps physicians diagnose and treat breast cancer: Study

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

New test indicates bone marrow cell therapy may benefit MS patients

DGIMED ORTHO receives 510(k) clearance for DISTALOCK Titanium Femoral Intramedullary Nail system

Making stem cells in the lab: a training program and a study

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Study shows training in rhythmic gymnastics improves bone health in adolescent girls

Investment report on Misonix from MicroStockProfit.com

ARIAD restructures collaboration with Merck for ridaforolimus mTOR inhibitor

Seniors who consume high dietary protein are less likely to suffer hip fractures

States rely on federal funds to buttress Medicaid programs; Worry about the future

AdvaCAL named official partner of National Osteoporosis Foundation

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Clinical development of RG7128 is on track: Pharmasset

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Surgeons can now customize artificial knee implants, prevent future revision surgeries

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News